PML and B-cell chronic lymphocytic leukemia: Idelalisib (FDA-approved 2014), a PI3Kδ inhibitor indicated for relapsed CLL (with rituximab), follicular B-cell NHL, and small lymphocytic lymphoma, has been associated with PML-immune reconstitution inflammatory syndrome in a CLL patient after multiple prior treatments and ASCT (41).